Drug combinations for ADHD
Contrary to commonly held beliefs, there are multiple ways to combine medications in ADHD (augmentation).1
A medical registry analysis found that a combination of different ADHD medication drug classes was used in between 10.3% (for sufferers with health insurance) and 24.3% (for sufferers with Medicaid “insurance”) of all 1,125,119 or 721,986 months of treatment.2
When combination medication was used, the following drug classes were most commonly involved:2
- Unretarded stimulants: 70.0%
- Α2-adrenergic agonists (guanfacine, clonidine): 63.8%
- Half-day-retarded stimulants: 51.8 %
Another study found that about a quarter of ADHD-affected children and adolescents who received stimulants also received supplemental medications:3
- Children: approx. 24 %
- Teenagers: approx. 26.7
The most common additional medications given were:
- Children: approx. 7.4
- Teenagers: approx. 13.8
- Atypical antipsychotics
- Children approx. 4.8
- Teenagers: approx. 5.8
- Children approx. 6 %
- Teenagers: approx. 3 %
Barkley reports that the typical ADHD medications each address about 70% of the same brain regions, but also target about 30% of other brain regions. Therefore, he recommends combination medications to achieve a broader effect with fewer side effects.4
All combinations or intake options described below are based on studies or reports of affected persons, which were made in consultation with the treating physician. It is expressly warned against unauthorized dosage or intake handling by affected persons!
- 1. Methylphenidate preparations among each other
- 2. Amphetamine drugs among themselves
- 3. Amphetamine drugs and methylphenidate
- 4. Guanfacine/clonidine in addition to stimulants
- 5. Atomoxetine in combination with other ADHD drugs
- 6. MPH and tipepidine
- 7. Desipramine and stimulants
- 8. Combination medication with other substances
9. Combination therapy with ADHD medication for comorbid disorders
9.1. Depression or anxiety and ADHD
- 9.1.1. Fluoxetine and MPH in comorbid depression and ADHD
- 9.1.2. Atomoxetine and antidepressants for comorbid anxiety or depression and ADHD
- 9.1.3. Vortioxetine and methylphenidate in comorbid ODD, anxiety, and ADHD
- 9.1.4. Duloxetine alleviates comorbid enuresis and stimulant-induced dysphoria in ADHD
- 9.2. Disruptive Mood Dysregulation Disorder (DMDD) and ADHD
- 9.3. Behavioral disorders or tics and ADHD
- 9.4. Obsessive-compulsive disorder and ADHD
- 9.5. Sleep problems and ADHD
- 9.1. Depression or anxiety and ADHD
1. Methylphenidate preparations among each other
It is possible to combine different methylphenidate preparations, especially retarded and unretarded, without any problems.
Unretarded MPH has its special significance in balancing the duration of action and adapting to special stress situations. Unretarded MPH can prolong the duration of action in the afternoon or early evening or bridge the time in the morning until the appropriate intensity of action of the sustained-release preparation is reached.
One study found that 40% of adults with ADHD receive such a combination to extend daytime coverage.5Similarly, Mason reports from his own medical practice that most of his adult ADHD patients take sustained-release stimulants, which typically last 8-10 hours, so most of them need additional unretarded medications to supplement to get through the day.6
Occasionally, (experienced) sufferers report that they cope better with 2 different half-day MPH retard preparations in the morning and early afternoon than with taking the same retard preparation again. These sufferers also often use unretarded MPH to extend the day’s coverage.
It must be mentioned that the fine-tuning of such combinations is mostly done by the patient himself, and requires that the attending physician recognizes the necessary sense of responsibility to accompany him in the adequate adjustment of medication. In the case of children, this may be difficult to achieve, especially if the medication is already difficult to take evenly throughout the day.
2. Amphetamine drugs among themselves
Combining different amphetamine medications is usually done not to improve symptoms or reduce side effects but to provide better daytime coverage.
Some patients report good experiences with a combination of attentin (unretarded D-amphetamine) and retarded amphetamine (Elvanse). While Elvanse releases the amphetamine bound to lysine only very slowly via the intestine and blood, which can take up to 2 hours until the full onset of effect, a noticeable onset of effect is reported for attentin after about 15 minutes, which corresponds to unretarded MPH.
While Elvanse is effective for 10 to 11 hours from ingestion in most sufferers (a few sufferers report metabolization within 6 hours, with isolated cases even much faster), Attentin has an effective time of around 5 hours.
Some people have good experiences with taking a small dose of attentin in the morning and Elvanse at the same time or a few hours later. Others report that taking Attentin in the afternoon or early evening helps them get through a long day. In all cases, the Elvanse dose is reduced somewhat after a previous attentine dose.
In addition, quite a few sufferers report that those who manage best with two smaller doses of Elvanse taken at different times.
While quite a number of people affected by Elvanse report improved evening sleepiness and thus improved ability to fall asleep, if the ability to fall asleep worsens and does not subside even after several weeks, consideration should be given to changing the times at which the drug is taken in order to achieve an earlier end to the effective period.
3. Amphetamine drugs and methylphenidate
Many patients report taking amphetamine medications and (especially unretarded) MPH on the same day, in consultation with their physician. No negative experiences are known,
Again, the greatest importance of (unretarded) MPH is in the time-delayed addition of the duration of action of the retarded amphetamine drug (Elvanse) early in the morning or in the evening.
In the (rather rare) cases in which MPH or AMP alone does not have sufficient effect up to the respective usually acceptable daily doses, parallel administration of MPH and AMP is also possible.
In addition, there are several medications that can support the effect of other medications in ADHD.
4. Guanfacine/clonidine in addition to stimulants
A larger randomized double-blind placebo-controlled trial over 9 weeks in children with inadequate ADHD symptom improvement with stimulants showed significant improvements with guanfacine given in addition without additional side effects. Apparently, several publications treat the same study.789
Several other studies also found positive results of augmentative administration of guanfacine in ADHD sufferers who were not optimally adjusted with stimulants alone, in relation to children10 and in relation to children and adolescents.11
Another double-blind placebo-controlled study in 50 children 6 to 12 years of age with ADHD found improvement in executive functions with individually optimized guanfacine administration, which was in addition to previous stimulants, without additional side effects.12 A study on effects of combined administration of guanfacine and MPH on EEG in children with ADHD confirms the results.13
A randomized double-blind comparative trial between monotherapy with MPH or guanfacine and combination medication with MPH and guanfacine found a small but consistent benefit of combination therapy in reducing inattentive subscale scores of ADHD-RS-IV and a greater response rate (responding) than monotherapy. Combination therapy showed no serious cardiovascular events. Sedation, somnolence, lethargy, and fatigue were greater with guanfacine monotherapy as with combination therapy. All treatments were well tolerated.14 Another (?) randomized double-blind trial by the same authors from the same year concluded that combined treatment with MPH and guanfacine resulted in greater improvements in working memory than placebo or guanfacine alone, but was not superior to monotherapy with MPH, even in other cognitive domains.15 Combination therapy of MPH and guanfacine showed smaller cardiovascular effects than monotherapy of MPH or guanfacine.16
Guanfacine, which like clonidine is an α₂-adrenoceptor agonist, appears to be approved in some countries for combination medication with stimulants in ADHD,17 and in children with ADHD who respond poorly to stimulants alone, together with stimulants improves symptoms significantly more than stimulants alone.
A randomized double-blind placebo-controlled trial of adults with ADHD who had unsatisfactory improvements in their ADHD symptoms with stimulants and who were also individually augmented with 1 to 6 mg guanfacine showed significant improvement in the guanfacine group and, surprisingly, likewise in the placebo group. Increased side effects were not found.18 Two studies in healthy adults also found no complications with combination medication of guanfacine with lisdexamfetamine (Elvanse) and MPH.1920 In a single case, it was reported that clonidine given augmentatively could eliminate MPH-induced nocturnal teeth grinding.21
It would be interesting to know whether guanfacine/clonidine might also be able to reduce other tension-reducing actions (nail biting, lip biting) that sometimes occur as side effects with stimulants. An individual case report is not yet sufficient evidence for this.
One study came to a positive result of augmenting administration of clonidine to stimulants in ADHD.22 Nevertheless, guanfacine should be preferred today due to its lower side effect profile.
5. Atomoxetine in combination with other ADHD drugs
5.1. Atomoxetine and stimulants
Although there is no official approval of a combination medication of atomoxetine and other ADHD-indicated medications, a study2 found the use of such a combination medication in
- 22.2% of those aged 6-17 with health insurance coverage
- 9.8 % of those with health insurance aged 18 and over
- 36.1% of Medicaid ADHD(H)S beneficiaries.
Another study reported 824 sufferers who received combination therapy of atomoxetine and methylphenidate.23
Ryffel-Rawak cites a personal communication from J. Krause that atomoxetine is effective primarily in combination with stimulants.24
Brown reports 4 cases in which only combination therapy of atomoxetine with stimulants produced adequate improvement in ADHD symptoms.25
reports that in 2003, when atomoxetine came onto the market, he switched 35 children with ADHD from stimulants to atomoxetine. To ensure that the switch was as smooth as possible, the previous stimulant dose was initially halved in a first step and supplemented with half the target dose of atomoxetine. after 14 days, the complete switch to the atomoxetine target dose was made in a second step. Surprisingly, about half of the subjects asked to continue the combination of reduced stimulants and half the atomoxetine dose. This combination therapy proved to be very successful. Most sufferers significantly reduced their previous stimulant dose. Side effects were less than in patients receiving stimulants alone. In particular, those on the combination therapy reported that family life had improved because the meltdowns, which many families already considered normal outside the stimulant period, had decreased. This seems to us a plausible consequence of the fact that atomoxetine, as a level medication, remains effective throughout the day, whereas stimulants have only a limited time during the day.
Mason6 reports on a study by Wilens in 2006 at Harvard in which atomoxetine and sustained-release MPH (Concerta) were each combined in high doses to test the maximum possible symptom reduction. Patients who completed the study would have shown symptom reductions of more than 90%. Their ADHD symptoms had disappeared and attention was normal.
However, it was problematic that the high drug dosage used here triggered intolerable side effects in many patients, which was due to the study design, which had aimed solely at maximum symptom improvement.
A study (albeit funded by atomoxetine manufacturer Lilly) found no benefit in symptom improvement with combination therapy of atomoxetine with other ADHD medications compared to monotherapy (possibly because prescribing was based on individual need by the treating physicians and was not the same for all subjects in a group), but also no higher side effects than with monotherapy with atomoxetine (the figures, however, show reduced side effects with combination therapy).26 It should be noted that atomoxetine alone generally has significantly higher side effects than stimulants alone.
A review article of 16 studies showed that combination medication of atomoxetine and stimulants was mostly due to an unsatisfactory response to monomedication. Most of these were male children and adolescents with ADHD-C. Combination of atomoxetine with methylphenidate was most commonly reported. In some, but not all, affected individuals, the combination medication improved symptoms. No serious adverse events were reported.27
Another review reported that administration of atomoxetine alongside stimulants was problem-free, at least during a meictation change.28
Another study reported symptom improvement by additional administration of sustained-release MPH in ADHD-affected children who did not show sufficient symptom improvement on atomoxetine.29 That increased side effects occurred within the first 4 weeks of combination therapy (i.e., during the dosing phase of the additionally given MPH),30 is not particularly surprising. More relevant is the side effect profile after the dosing phase.
Another study also reported significant symptom improvements with combination therapy of atomoxetine and methylphenidate compared with monotherapy.23
Mason6 reports from his own medical practice that most of his adult ADHD patients take retarded stimulants that typically last for 8-10 hours, so most of them need additional unretarded medications to supplement to get through the day.
In contrast, those patients in his practice who take a combination of atomoxetine with stimulants use low to moderate doses of stimulants and report a duration of action greater than 12 hours.
Mason reports isolated cases:
- In one case, the previous administration of 72 mg MPH per day (with an unsatisfactory symptom reduction of 25%) was changed to 27 mg MPH and 60 mg atomoxetine per day. This resulted in an 80% symptom reduction, which persisted for many years without adjustment effects.
- In another single case, a reduction in amphetamine medication (Adderall) from 50 to 30 mg/day with concomitant administration of 40 mg atomoxetine/day resulted in an improvement in symptom reduction to 67%.
Further improvement to now 74% symptom reduction resulted from switching from 50 mg Adderall to 50 mg Vyvanse (in EU: Elvanse), equivalent to 20 mg Adderall, while continuing 40 mg atomoxetine.
Mason himself points out that not every sufferer experienced (such) improvements by switching to combination therapy of atomoxetine and stimulants.
Finally, Mason points to the experience of other physicians who achieved comparable positive effects by supplementing stimulants with guanfacine, bupropion, or antidepressants.
One study reported reduced drug discontinuation with a combination of stimulants and atomoxetine compared with each taken alone.31 This is likely to indicate a reduced rate of side effects.
Barkley, in a presentation, reports benefits of combining stimulants and atomoxetine to counter stimulant-induced dampening of the limbic system and the accompanying diminished emotion perception.32
A German neurologist we know often works with a combination of stimulants and bupropion (mostly for ADHD-I, not ADHD-HI or ADHD-C, due to the activating effect of bupropion).
5.2. Atomoxetine and hopantenic acid
A Russian article describes benefits of augmentative administration of hopantenic acid (Phenibut, Pantogam) in children with ADHD.33 A single case report by the same lead author suggests similar results.34
Hopantenic acid decreased the D2 receptor in mice even slightly more than atomoxetine and additionally increased the GABAB receptor.35
Hopantenic acid (N-pantoyl-GABA) is more commonly used in Russia to treat ADHD. It is not approved in the USA and the EU.
The evidence on hopantenic acid is too imprecise to recommend treatment with it.
6. MPH and tipepidine
Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) increases dopamine levels via inhibition of GIRK channels, but without increasing motor activity or producing methamphetamine-like behavioral sensitization.
It has been used in Japan since 1959 and could be an interesting alternative to MPH and AMP due to its lack of stimulant properties.36
Tipepidine alone shows significant improvements in ADHD symptomatology.37
A placebo-based double-blind study found a beneficial effect of tipepidine given in addition to MPH.38
7. Desipramine and stimulants
One study found no adverse interactions of combination therapy with desipramine and stimulants.39
Desipramine is the active metabolite of imipramine. Desipramine drugs are now largely out of circulation. Mutual reinforcement is known to occur between imipramine and MPH as an interaction,
8. Combination medication with other substances
The active ingredients listed below are not prescription drugs. They can, like the additional administration of vitamins, minerals or polyunsaturated fatty acids, support the treatment of ADHD,
In the following, studies are presented that were explicitly prepared for combination therapy with stimulants. However, the administration of vitamins, minerals or polyunsaturated fatty acids in addition to stimulants is not subject to any particular concerns.
8.1. Resveratrol next to MPH
Resveratrol is an antioxidant.
A double-blind placebo-controlled study found positive effects with 500 mg resveratrol in addition to the MPH given anyway in children with ADHD in parent ratings but not in teacher ratings.40
8.2. L-Carnosine next to MPH
L-carnosine is a bioactive dipeptide consisting of the amino acids ß-alanine and histidine.
A double-blind placebo-controlled study found positive effects with 800 mg L-carnosine in addition to the MPH given anyway in children with ADHD in parent ratings but not in teacher ratings.41
8.3. Zinc sulfate next to MPH
A double-blind placebo-controlled study in children with ADHD found positive effects of zinc sulfate medicated in addition to the MPH given anyway.42
8.4. L-Methylfolate next to MPH
A study of augmentation of optimally adjusted MPH with 15 mg L-methylfolate in 44 adults with ADHD showed no improvement but rather increased MPH requirements.43
9. Combination therapy with ADHD medication for comorbid disorders
9.1. Depression or anxiety and ADHD
9.1.1. Fluoxetine and MPH in comorbid depression and ADHD
A study of ADHD patients with comorbid depression who did not show sufficient improvement in ADHD symptoms with MPH alone found significant improvements in ADHD symptoms in almost all subjects with augmentative fluoxetine. In 40% of the subjects, an additional administration of less than 20 mg of fluoxetine was sufficient. There were no increased side effects.44
Fluoxetine is believed to be the only SSRI with a drive-enhancing effect. As monotherapy, it does not appear to be suitable for the treatment of ADHD. ⇒ Fluoxetine in ADHD
Co-administration of MH and fluoxetine to juvenile rats produced increased sensitivity to reward stimuli (which should be positive in ADHD) and increased anxiety and stress sensitivity (which would be detrimental in ADHD) in adult animals.45 However, healthy animals and not ADHD model animals were tested.
9.1.2. Atomoxetine and antidepressants for comorbid anxiety or depression and ADHD
22.214.171.124. Atomoxetine and fluoxetine
A double-blind placebo-controlled study investigated combination treatment with atomoxetine and fluoxetine (an SSRI) compared with monotherapy with atomoxetine in children and adolescents with ADHD and comorbid symptoms of depression or anxiety. The study found no relevant improvements in ADHD symptoms with combination treatment. Small improvements were found in the symptomatology of comorbid depression with combination therapy compared with monotherapy with atomoxetine, with the latter already improving symptoms of depression and anxiety in addition to ADHD symptoms. The combination treatment did not show increased side effects. Blood pressure with combination therapy was slightly more elevated than with monotherapy.46
126.96.36.199. Atomoxetine and SSRI / SNRI
One study examined combination treatment of atomoxetine with SNRI and SSRI in adults with ADHD and comorbid generalized anxiety disorder. In all subjects, SNRI or SRI alone failed to improve anxiety symptoms. Combination treatment of SNRI or SSRI with atomoxetine showed significant improvements in anxiety symptoms compared with prior monotherapy with SNRI/SSRI.47
9.1.3. Vortioxetine and methylphenidate in comorbid ODD, anxiety, and ADHD
A single case report noted a good long-term effect of a combination medication of vortioxetine (10 mg/day) and MPH on stimulant-induced anxiety and ADHD symptomatology in a 15-year-old ADHD sufferer who did not respond to atomoxetine, reacted to MPH with dysphoria, and did not tolerate augmenting clonidine. This was achieved with high tolerability.48
9.1.4. Duloxetine alleviates comorbid enuresis and stimulant-induced dysphoria in ADHD
A single case report noted relief of comorbid enuresis (wetting), stimulant-induced dysphoria, and improvement in cognitive abilities in an adolescent with ADHD.49
9.2. Disruptive Mood Dysregulation Disorder (DMDD) and ADHD
DMDD is characterized by persistent severe irritability and high impulsivity. ADHD often occurs comorbidly.
9.2.1. Aripiprazole and methylphenidate in DMDD and ADHD
One study found a positive effect of combination therapy of aripiprazole and methylphenidate children with comorbid DMDD and ADHD. Increased side effects were not found.50
9.3. Behavioral disorders or tics and ADHD
Conduct disorder or tics are often treated with antipsychotics.
One study found among children and adolescents who began medication with methylphenidate from 2005 to 2013, 67,595 children received combination therapy of MPH and antipsychotics. Among them was a combination with
- Risperidone (72%)
- Pipamperone (15 %)
- Tiapride (8%)
A quarter of users of combination therapy of MPH and antipsychotics were prescribed it only once.
Use of the combinations of MPH with risperidone and tiapride was frequently appropriate (>72%), whereas use of the MPH-pipamperone combination was rarely appropriate (<15%).51
In comorbid ODD and ADHD, combination treatment with risperidone and MPH proved helpful.52
Barkley, in a presentation, reported benefits of combining stimulants and guanfacine (which was helpful for comorbid tics) to counter the stimulant-induced dampening of the limbic system and the accompanying decreased emotion perception.53
9.4. Obsessive-compulsive disorder and ADHD
9.4.1. Sertraline and guanfacine and behavioral therapy
A report of 2 children with compulsivity and ADHD (9 and 10 years) might indicate a positive effect of a combination of behavioral therapy, sertraline, and guanfacine.54
9.5. Sleep problems and ADHD
9.5.1. Melatonin and stimulants
A Swedish cohort study found that two-thirds of boys and half of girls who received melatonin also received ADHD medication.55
Molife, Bernauer, Farr, Haynes, Kelsey (2012): Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations. Postgrad Med. 2012 Sep;124(5):7-22. doi: 10.3810/pgm.2012.09.2586. PMID: 23095422. ↥ ↥ ↥
Zhou, Betts, Bocharova, Kinrich, Spalding (2020): Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States. J Atten Disord. 2020 Jan;24(2):336-347. doi: 10.1177/1087054718784668. PMID: 29991300; PMCID: PMC6939321. n = ca. 960.000 ↥
Barkley (2014): Dr Russell Barkley on ADHD Meds and how they all work differently from each other; Youtube – Langfassung, ca. bei 1 Stunde 4 Minuten ↥
Mason (2020): How a Physician Treats ADHD with Combination Therapy, additudemag.com, Stand Oktober 2020 ↥ ↥ ↥ ↥
Wilens, Bukstein, Brams, Cutler, Childress, Rugino, Lyne, Grannis, Youcha (2012): A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan;51(1):74-85.e2. doi: 10.1016/j.jaac.2011.10.012. PMID: 22176941. n = 461 ↥
Cutler, Brams, Bukstein, Mattingly, McBurnett, White, Rubin (2014): Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014 Oct;53(10):1092-101. doi: 10.1016/j.jaac.2014.08.001. PMID: 25245353. n = 461 ↥
Wilens, McBurnett, Turnbow, Rugino, White, Youcha (2017): Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD. J Atten Disord. 2017 Jan;21(2):110-119. doi: 10.1177/1087054713500144. PMID: 24071772. n = 461 ↥
Meyers, Gajria, Candrilli, Fridman, Sikirica (2017):. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-125. doi: 10.2217/cer-2016-0039. PMID: 28118752. n = 165 ↥
Spencer, Greenbaum, Ginsberg, Murphy (2009): Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):501-10. doi: 10.1089/cap.2008.0152. PMID: 19877974; PMCID: PMC2861960. n = 75 ↥
van Stralen (2020): A Controlled Trial of Extended-Release Guanfacine and Psychostimulants on Executive Function and ADHD. J Atten Disord. 2020 Jan;24(2):318-325. doi: 10.1177/1087054717751197. PMID: 29313415. n = 50 ↥
Loo, Bilder, Cho, Sturm, Cowen, Walshaw, Levitt, Del’Homme, Piacentini, McGough, McCracken (2016): Effects of d-Methylphenidate, Guanfacine, and Their Combination on Electroencephalogram Resting State Spectral Power in Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2016 Aug;55(8):674-682.e1. doi: 10.1016/j.jaac.2016.04.020. PMID: 27453081; PMCID: PMC5003618. n = 179 ↥
McCracken, McGough, Loo, Levitt, Del’Homme, Cowen, Sturm, Whelan, Hellemann, Sugar, Bilder (2016): Combined Stimulant and Guanfacine Administration in Attention-Deficit/Hyperactivity Disorder: A Controlled, Comparative Study. J Am Acad Child Adolesc Psychiatry. 2016 Aug;55(8):657-666.e1. doi: 10.1016/j.jaac.2016.05.015. PMID: 27453079; PMCID: PMC4976782. n = 207 ↥
Bilder, Loo, McGough, Whelan, Hellemann, Sugar, Del’Homme, Sturm, Cowen, Hanada, McCracken (2016): Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2016 Aug;55(8):667-73. doi: 10.1016/j.jaac.2016.05.016. Epub 2016 Jun 7. PMID: 27453080; PMCID: PMC4964604. n = 275 ↥
Sayer, McGough, Levitt, Cowen, Sturm, Castelo, McCracken (2016): Acute and Long-Term Cardiovascular Effects of Stimulant, Guanfacine, and Combination Therapy for Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2016 Dec;26(10):882-888. doi: 10.1089/cap.2015.0264. Epub 2016 Aug 2. PMID: 27483130; PMCID: PMC5178010. n = 207 ↥
Childress (2012): Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. Adv Ther. 2012 May;29(5):385-400. doi: 10.1007/s12325-012-0020-1. PMID: 22610723. REVIEW ↥
Butterfield, Saal, Young, Young (2016): Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. Psychiatry Res. 2016 Feb 28;236:136-141. doi: 10.1016/j.psychres.2015.12.017. PMID: 26730446. n = 26 ↥
Roesch, Corcoran, Fetterolf, Haffey, Martin, Preston, Purkayastha, Wang, Ermer (2013): Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs R D. 2013 Jun;13(2):119-28. doi: 10.1007/s40268-013-0014-8. PMID: 23615868; PMCID: PMC3689918. n = 42 ↥
Roesch, Corcoran, Haffey, Stevenson, Wang, Purkayastha, Martin, Ermer (2013): Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D. 2013 Mar;13(1):53-61. doi: 10.1007/s40268-013-0009-5. PMID: 23519656; PMCID: PMC3627016. n = 38 ↥
Naguy, Elsori, Alamiri (2019): Methylphenidate-Induced Nocturnal Bruxism Alleviated by Adjunctive Clonidine. J Child Adolesc Psychopharmacol. 2019 Feb;29(1):75-76. doi: 10.1089/cap.2018.0114. PMID: 30575406. ↥
Childress, Sallee (2012): Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. Drugs Today (Barc). 2012 Mar;48(3):207-17. doi: 10.1358/dot.2012.48.3.1750904. PMID: 22462040. REVIEW ↥
Ozbaran, Kose, Yuzuguldu, Atar, Aydin (2015): Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder. World J Biol Psychiatry. 2015;16(8):619-24. doi: 10.3109/15622975.2015.1051109. PMID: 26223958. n = 12 ↥ ↥
Brown (2004): Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports. J Child Adolesc Psychopharmacol. 2004 Spring;14(1):129-36. doi: 10.1089/104454604773840571. PMID: 15142400. ↥
Clemow, Mason, Sarkis, Ruff, Berman, Donnelly, Rob, Holland, Schuh, Barnes, Araujo (20115): Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study. Expert Rev Neurother. 2015;15(11):1353-66. doi: 10.1586/14737175.2015.1102060. PMID: 26488905. ↥
Treuer, Gau, Méndez, Montgomery, Monk, Altin, Wu, Lin, Dueñas (2013): A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability. J Child Adolesc Psychopharmacol. 2013 Apr;23(3):179-93. doi: 10.1089/cap.2012.0093. PMID: 23560600; PMCID: PMC3696926. REVIEW ↥
Prasad, Steer (2008): Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence. Paediatr Drugs. 2008;10(1):39-47. doi: 10.2165/00148581-200810010-00005. PMID: 18162007. REVIEW ↥
Wilens, Hammerness, Utzinger, Schillinger, Georgiopoulous, Doyle, Martelon, Brodziak (2009): An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):485-92. doi: 10.1089/cap.2008.0125. PMID: 19877972; PMCID: PMC2861954. n = 50 ↥
Hammerness, Georgiopoulos, Doyle, Utzinger, Schillinger, Martelon, Brodziak, Biederman, Wilens (2009): An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):493-9. doi: 10.1089/cap.2008.0126. PMID: 19877973; PMCID: PMC2861956. n = 50 ↥
Bahn, Seo (2021) Combined Medication with Stimulants and Non-stimulants for Attention-deficit/hyperactivity Disorder. Clin Psychopharmacol Neurosci. 2021 Nov 30;19(4):705-711. doi: 10.9758/cpn.2021.19.4.705. PMID: 34690125. ↥
Kupriyanova, Koren, Alabusheva (2017): Strategiia povysheniia éffektivnosti psikhofarmakologicheskogo lecheniia giperkineticheskogo rasstroĭstva povedeniia s primeneniem pantogama [A strategy for increasing the efficiency of psychopharmacological treatment of hyperkinetic behavior disorder with pantogam]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(11. Vyp. 2):75-79. Russian. doi: 10.17116/jnevro201711711275-79. PMID: 29359723. n = 24 ↥
Kupriyanova, Koren (2016): Povyshenie effektivnosti lecheniya giperkineticheskikh rasstroistv s primeneniem pantogama [Pantogam augmentation in hyperkinetic behavior disorder treatment]. Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(6):66-69. Russian. doi: 10.17116/jnevro20161166166-69. PMID: 27456906. ↥
Kovalev, Sukhorukova, Vasileva, Kondrakhin, Salimov (2021): Vliianie pantogama i atomoksetina na ustoĭchivost’ vnimaniia i raspredelenie dofaminovykh D2 i GAMKV-retseptorov u mysheĭ s model’iu defitsita vnimaniia [Influence of pantogam and atomoxetine on attention stability and distribution of dopamine D2 and GABAB receptors in the attention deficit mouse model]. Biomed Khim. 2021 Sep;67(5):402-410. Russian. doi: 10.18097/PBMC20216705402. PMID: 34730553. ↥
Sasaki, Hashimoto, Tachibana, Kurata, Okawada, Ishikawa, Kimura, Komatsu, Ishikawa, Hasegawa, Shiina, Hashimoto, Kanahara, Shiraishi, Iyo (2014): Tipepidine in children with attention deficit/hyperactivity disorder: a 4-week, open-label, preliminary study. Neuropsychiatr Dis Treat. 2014 Jan 24;10:147-51. doi: 10.2147/NDT.S58480. eCollection 2014. ↥
Dehbozorghi, Bagheri, Moradi, Shokraee, Mohammadi, Akhondzadeh (2019): Efficacy and safety of tipepidine as adjunctive therapy in children with attention-deficit/hyperactivity disorder: Randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci. 2019 Nov;73(11):690-696. doi: 10.1111/pcn.12913. PMID: 31294924. n = 53 ↥
Cohen, Prince, Biederman, Wilens, Faraone, Whitt, Mick, Spencer, Meyer, Polisner, Flood (1999): Absence of effect of stimulants on the phamacokinetics of desipramine in children. Pharmacotherapy. 1999 Jun;19(6):746-52. doi: 10.1592/phco.19.9.746.31539. PMID: 10391421. n = 142 ↥
Rafeiy-Torghabeh, Ashraf-Ganjouei, Moradi, Bagheri, Mohammadi, Akhondzadeh (2020): Resveratrol adjunct to methylphenidate improves symptoms of attention-deficit/hyperactivity disorder: a randomized, double-blinded, placebo-controlled clinical trial. Eur Child Adolesc Psychiatry. 2020 May 24. doi: 10.1007/s00787-020-01562-z. PMID: 32449130. n = 66 ↥
Ghajar, Aghajan-Nashtaei, Afarideh, Mohammadi, Akhondzadeh (2018): l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):331-338. doi: 10.1089/cap.2017.0157. PMID: 29469593. n = 56 ↥
Akhondzadeh, Mohammadi, Khademi (2004): Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371]. BMC Psychiatry. 2004 Apr 8;4:9. doi: 10.1186/1471-244X-4-9. PMID: 15070418; PMCID: PMC400741. n = 44 ↥
Surman, Ceranoglu, Vaudreuil, Albright, Uchida, Yule, Spencer, Boland, Grossman, Rhodewalt, Fitzgerald, Biederman (2019): Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Clin Psychopharmacol. 2019 Jan/Feb;39(1):28-38. doi: 10.1097/JCP.0000000000000990. PMID: 30566416; PMCID: PMC6750952. n = 44 ↥
Gammon, Brown (1993): Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol. 1993 Spring;3(1):1-10. doi: 10.1089/cap.1993.3.1. PMID: 19630593. n = 32 ↥
Warren, Iñiguez, Alcantara, Wright, Parise, Weakley, Bolaños-Guzmán (2011): Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood. J Neurosci. 2011 Jul 13;31(28):10347-58. doi: 10.1523/JNEUROSCI.1470-11.2011. PMID: 21753012; PMCID: PMC3139175. ↥
Kratochvil, Newcorn, Arnold, Duesenberg, Emslie, Quintana, Sarkis, Wagner, Gao, Michelson, Biederman (2005): Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. doi: 10.1097/01.chi.0000169012.81536.38. PMID: 16113620. n = 173 ↥
Gabriel A, Violato C. Adjunctive atomoxetine to SSRIs or SNRIs in the treatment of adult ADHD patients with comorbid partially responsive generalized anxiety (GA): an open-label study. Atten Defic Hyperact Disord. 2011 Dec;3(4):319-26. doi: 10.1007/s12402-011-0063-1. Epub 2011 Aug 11. PMID: 21833565. n = 29 ↥
Naguy A, Alamiri B. Successful Add-on Vortioxetine for an Adolescent With Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol. 2018 Aug;38(4):407-409. doi: 10.1097/JCP.0000000000000912. PMID: 29912797. ↥
Naguy (2016): Duloxetine Alleviates Stimulant Dysphoria, Helps With Enuresis, and Complements Cognitive Response in an Adolescent With Attention-Deficit/Hyperactivity Disorder. Prim Care Companion CNS Disord. 2016 Dec 29;18(6). doi: 10.4088/PCC.16l01957. PMID: 28033457. ↥
Pan, Fu, Yeh (2018): Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study. J Child Adolesc Psychopharmacol. 2018 Dec;28(10):682-689. doi: 10.1089/cap.2018.0068. PMID: 30148656. n = 24 ↥
Scholle, Banaschewski, Enders, Garbe, Riedel (2018): Use and Characteristics of Antipsychotic/Methylphenidate Combination Therapy in Children and Adolescents with a Diagnosis of Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2018 Jul/Aug;28(6):415-422. doi: 10.1089/cap.2018.0024. PMID: 29768038. n = 67.595 ↥
Jahangard, Akbarian, Haghighi, Ahmadpanah, Keshavarzi, Bajoghli, Sadeghi Bahmani, Holsboer-Trachsler, Brand (2017): Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed – Results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017 May;251:182-191. doi: 10.1016/j.psychres.2016.12.010. PMID: 28213188. n = 84 ↥
Taormina, Galloway, Rosenberg (2016): Treatment Efficacy of Combined Sertraline and Guanfacine in Comorbid Obsessive-Compulsive Disorder and Attention Deficit/Hyperactivity Disorder: Two Case Studies. J Dev Behav Pediatr. 2016 Jul-Aug;37(6):491-5. doi: 10.1097/DBP.0000000000000290. PMID: 27011005; PMCID: PMC4930387. ↥
Furster, Hallerbäc (2015): The use of melatonin in Swedish children and adolescents–a register-based study according to age, gender, and medication of ADHD. Eur J Clin Pharmacol. 2015 Jul;71(7):877-81. doi: 10.1007/s00228-015-1866-3. PMID: 25995170. n = 7.389 ↥